Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rRSV A/Maryland/001/11 Challenge Study
NCT03624790Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Oct 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of rRSV A/Maryland/001/11 in respiratory syncytial virus infection (RSV) (2 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency and Severity of Challenge Virus-Related Solicited Signs and Symptoms at Day 56, Frequency and Severity of Adverse Events at Day 56 and 5 more. Started Jul 2018; status: completed.
02
Drugs
rRSV A/Maryland/001/11
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03624790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624790.